JP2007507207A5 - - Google Patents

Download PDF

Info

Publication number
JP2007507207A5
JP2007507207A5 JP2006528190A JP2006528190A JP2007507207A5 JP 2007507207 A5 JP2007507207 A5 JP 2007507207A5 JP 2006528190 A JP2006528190 A JP 2006528190A JP 2006528190 A JP2006528190 A JP 2006528190A JP 2007507207 A5 JP2007507207 A5 JP 2007507207A5
Authority
JP
Japan
Prior art keywords
vlp
protein
vaccine
recombinant
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006528190A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007507207A (ja
JP5451960B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/031326 external-priority patent/WO2005032586A1/en
Publication of JP2007507207A publication Critical patent/JP2007507207A/ja
Publication of JP2007507207A5 publication Critical patent/JP2007507207A5/ja
Application granted granted Critical
Publication of JP5451960B2 publication Critical patent/JP5451960B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006528190A 2003-09-29 2004-09-24 酵母におけるｈｐｖ４５ｌ１の最適化された発現 Expired - Lifetime JP5451960B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50681203P 2003-09-29 2003-09-29
US60/506,812 2003-09-29
PCT/US2004/031326 WO2005032586A1 (en) 2003-09-29 2004-09-24 Optimized expression of hpv 45 l1 in yeast

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011045589A Division JP2011152137A (ja) 2003-09-29 2011-03-02 酵母におけるｈｐｖ４５ｌ１の最適化された発現

Publications (3)

Publication Number Publication Date
JP2007507207A JP2007507207A (ja) 2007-03-29
JP2007507207A5 true JP2007507207A5 (enExample) 2011-05-06
JP5451960B2 JP5451960B2 (ja) 2014-03-26

Family

ID=34421558

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2006528190A Expired - Lifetime JP5451960B2 (ja) 2003-09-29 2004-09-24 酵母におけるｈｐｖ４５ｌ１の最適化された発現
JP2011045589A Pending JP2011152137A (ja) 2003-09-29 2011-03-02 酵母におけるｈｐｖ４５ｌ１の最適化された発現
JP2014129350A Pending JP2014221052A (ja) 2003-09-29 2014-06-24 酵母におけるｈｐｖ４５ｌ１の最適化された発現
JP2016019712A Pending JP2016136947A (ja) 2003-09-29 2016-02-04 酵母におけるｈｐｖ４５ｌ１の最適化された発現

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011045589A Pending JP2011152137A (ja) 2003-09-29 2011-03-02 酵母におけるｈｐｖ４５ｌ１の最適化された発現
JP2014129350A Pending JP2014221052A (ja) 2003-09-29 2014-06-24 酵母におけるｈｐｖ４５ｌ１の最適化された発現
JP2016019712A Pending JP2016136947A (ja) 2003-09-29 2016-02-04 酵母におけるｈｐｖ４５ｌ１の最適化された発現

Country Status (33)

Country Link
US (2) US7250170B2 (enExample)
EP (1) EP1673106B1 (enExample)
JP (4) JP5451960B2 (enExample)
KR (1) KR101165278B1 (enExample)
CN (1) CN1859923B (enExample)
AR (2) AR045804A1 (enExample)
AT (1) ATE435029T1 (enExample)
AU (1) AU2004277934B2 (enExample)
BE (1) BE2015C072I2 (enExample)
BR (1) BRPI0414845B8 (enExample)
CA (1) CA2539168C (enExample)
CY (2) CY1110525T1 (enExample)
DE (1) DE602004021828D1 (enExample)
DK (1) DK1673106T3 (enExample)
ES (1) ES2327530T3 (enExample)
FR (1) FR15C0083I2 (enExample)
HU (1) HUS1500063I1 (enExample)
IL (1) IL174458A (enExample)
IS (1) IS2694B (enExample)
LT (2) LTC1673106I2 (enExample)
LU (1) LU92902I2 (enExample)
MX (1) MXPA06003457A (enExample)
MY (1) MY140664A (enExample)
NL (1) NL300776I2 (enExample)
NO (3) NO339932B1 (enExample)
NZ (1) NZ545834A (enExample)
PL (1) PL1673106T3 (enExample)
PT (1) PT1673106E (enExample)
RU (1) RU2360001C2 (enExample)
SI (1) SI1673106T1 (enExample)
TW (1) TWI350853B (enExample)
WO (1) WO2005032586A1 (enExample)
ZA (1) ZA200601961B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
DK1730175T3 (da) 2004-03-24 2010-08-23 Merck Sharp & Dohme Geoptimaliseerde expressie van HPV 52 L1 in gist
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
WO2006113209A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006114312A2 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
EP2059262B1 (en) * 2006-08-28 2013-08-21 Sungkyunkwan University Foundation for Corporate Collaboration A dna vaccine for treating or preventing cervical cancer comprising a gene encoding hpv protein
US7709010B2 (en) * 2007-03-09 2010-05-04 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
EP2479186B1 (en) * 2007-11-23 2015-08-12 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein L1 of human papilloma viruses
KR101181907B1 (ko) 2009-06-19 2012-09-11 아이진 주식회사 자궁경부암 백신
WO2011149897A1 (en) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
AU2012270418B2 (en) * 2011-06-15 2015-08-13 Posvax Co., Ltd Method for enhancing the production yield of human papillomavirus L1 protein
EP2723371B1 (en) 2011-06-24 2019-10-23 Merck Sharp & Dohme Corp. Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
CN109321592A (zh) * 2012-01-21 2019-02-12 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN103361280B (zh) * 2012-03-28 2018-07-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
CN110423774A (zh) * 2013-04-26 2019-11-08 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN104120089B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN110295190A (zh) * 2013-05-17 2019-10-01 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv45 l1蛋白的方法
CN104513826B (zh) * 2013-09-29 2020-10-20 上海泽润生物科技有限公司 人乳头瘤病毒基因,及载体,菌株,表达方法
WO2015057541A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
BR112017004181A2 (pt) * 2014-09-11 2017-12-05 Cadila Healthcare Ltd ?gene, vetor, célula hospedeira, partículas similares a vírus, vacina para vírus de papiloma humano, composição imunogênica, adjuvante, método para o preparo de uma vacina de papiloma humano, proteína de capsídeo principal e proteína hpv l1?
CN106282278B (zh) * 2015-06-29 2021-06-08 广东东阳光药业有限公司 一种人乳头瘤病毒l1蛋白的发酵方法
CN106701798B (zh) * 2015-08-12 2021-09-17 北京康乐卫士生物技术股份有限公司 45型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750050B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒45亚型蛋白表达
CR20220395A (es) 2020-02-14 2022-10-27 Merck Sharp & Dome Llc Vacuna contra hpv
CN112680462B (zh) * 2020-12-29 2022-02-22 上海博唯生物科技有限公司 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
EP4380615A1 (en) 2021-08-06 2024-06-12 Merck Sharp & Dohme LLC Hpv vaccine
EP4387660A1 (en) 2021-08-19 2024-06-26 Merck Sharp & Dohme LLC Thermostable lipid nanoparticle and methods of use thereof
US20240408188A1 (en) 2023-06-09 2024-12-12 Merck Sharp & Dohme Llc Nanoemulsion adjuvant compositions for human papillomavirus vaccines

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ336696A3 (en) * 1994-05-16 1997-07-16 Merck & Co Inc Isolated and purified proteins of papillomavirus and process for preparing thereof
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
DE69836206T2 (de) 1997-02-07 2007-08-23 Merck & Co., Inc. Synthetische hiv gag gene
WO1998054339A1 (en) * 1997-05-27 1998-12-03 Hanil Synthetic Fiber Co., Ltd. PROCESS FOR PREPARING RECOMBINANT PROTEINS USING HIGHLY EFFICIENT EXPRESSION VECTOR FROM $i(SACCHAROMYCES CEREVISIAE)
EP1002091B1 (en) 1997-07-09 2012-02-29 Coridon Pty Limited Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
JP4440471B2 (ja) * 1998-08-14 2010-03-24 メルク エンド カムパニー インコーポレーテッド ヒトパピローマウイルスのウイルス様粒子の精製方法
EP1105157B1 (en) * 1998-08-14 2006-11-02 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
ATE290013T1 (de) * 1998-12-23 2005-03-15 Merck & Co Inc Neutralsierungs-assay, das humane papillomavirus- ähnliche partikel verwendet
ATE284898T1 (de) * 1999-08-25 2005-01-15 Merck & Co Inc Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
WO2002008435A1 (en) 2000-07-21 2002-01-31 Glaxo Group Limited Codon-optimized papilloma virus sequences
WO2003068993A1 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Method for isolation and purification of expressed gene products in vitro
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
ATE546529T1 (de) 2003-03-24 2012-03-15 Merck Sharp & Dohme Optimierte expression von hpv 31 l1 in hefe

Similar Documents

Publication Publication Date Title
JP2007507207A5 (enExample)
US7498036B2 (en) Optimized expression of HPV 58 L1 in yeast
US7482015B2 (en) Optimized expression of HPV 45 L1 in yeast
JP4505452B2 (ja) 酵母におけるｈｐｖ３１ｌ１の最適化発現
US7744892B2 (en) Optimized expression of HPV 52 L1 in yeast
TH82139A (th) การแสดงออกที่ถูกทำให้เหมาะสมของ hpv 45l1 ในยีสต์
TH72490B (th) การแสดงออกที่ถูกทำให้เหมาะสมของ hpv 45l1 ในยีสต์
TH64808B (th) การแสดงออกที่ถูกทำให้เหมาะสมของ hpv31 l1 ในยีสต์
HK1090953B (en) Optimized expression of hpv 31 l1 in yeast
TH74110A (th) การปรับแต่งการแสดงออกของ hpv58 l1 ในยีสต์ให้เหมาะสม
TH66992B (th) การปรับแต่งการแสดงออกของ hpv58 l1 ในยีสต์ให้เหมาะสม